Prostate adenocarcinoma

Researchers are testing whether giving radiation therapy before sipuleucel-T, a personalized immunotherapy vaccine, works better than the vaccine alone in men with hormone-resistant prostate cancer that has spread. The trial enrolls about 51 participants and randomly assigns them…

This early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…

This trial tests whether using 3D on-board imaging before each radiation session improves accuracy and outcomes for men with prostate cancer compared to standard imaging. The study tracks disease-free survival, side effects, and costs over 2 to 5 years. It aims to find the best i…

This phase 2 trial is testing whether surgery and radiation can help men whose prostate cancer has come back and spread to a few spots in the body. About 20 participants will receive either surgery to remove the spread tumors or targeted radiation, or both. The main goal is to se…

This study tested whether adding the drug niraparib to standard radiation and hormone therapy can help prevent high-risk prostate cancer from coming back. Niraparib blocks a protein that cancer cells use to repair their DNA, which may kill them. The trial enrolled 22 men with agg…

This study tested whether a shorter course of higher-dose radiation (hypofractionated) works as well as standard radiation after prostate removal in 296 men with prostate cancer. The main focus was on quality of life, especially urinary and bowel function. The goal is to find a t…

This study tests a type of radiation called high-dose brachytherapy for men with prostate cancer that hasn't spread. Doctors place tiny radioactive sources directly into the prostate to deliver a strong dose to the tumor while sparing nearby healthy tissue. The goal is to control…

This phase 2 trial tested phenelzine sulfate (Nardil), an antidepressant, in 26 men with prostate cancer that returned after initial treatment but hadn't spread. The goal was to see if the drug could lower PSA levels, a marker of cancer activity. Researchers measured how many pat…

This study tested whether giving a higher dose of radiation specifically to the visible tumor inside the prostate could improve cancer control in men with localized prostate cancer. Eighty-five men either received a standard radiation plan with an extra boost to the tumor or a co…

This study tested a new type of PET/MRI scan that uses a special tracer to find small spots of prostate cancer that standard scans miss. Men with a rising PSA after prostate surgery and radiation received targeted radiation to those spots. The goal was to see if this approach can…

This phase II trial tested a shorter course of higher-dose radiation (hypofractionation) in 53 men with high-risk prostate cancer who had already had their prostate removed. The goal was to see if this approach could control cancer while reducing side effects. Participants also r…

This study followed 354 men with low- to intermediate-risk prostate cancer who chose to freeze only the cancerous half of their prostate (hemi-gland cryoablation). Researchers tracked how well the treatment controlled the cancer and how it affected urinary function and quality of…

This study tested a new X-ray monitoring technique (KIM) during prostate cancer radiation therapy. The goal was to see if it helps doctors aim more precisely at the tumor while reducing harm to healthy tissue. 49 men with low- or intermediate-risk prostate cancer took part. The a…

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…

This study tested a new way to give radiation therapy for prostate cancer. It used very precise, high-dose radiation over just five days. The goal was to control the cancer while reducing side effects on the bladder and bowel. 444 men with localized prostate cancer took part, and…

This study tested whether adding a radioactive drug (radium-223) to standard targeted radiation (SBRT) can delay cancer progression in men whose prostate cancer has returned in a few bone spots but hasn't yet become hormone-resistant. Twelve men participated, receiving either the…

This study compared two radiation therapy schedules for men with intermediate- or high-risk prostate cancer. One group received fewer, higher-dose radiation sessions (hypofractionated), while the other received standard daily doses. Both groups also received hormone therapy. The …

This study tested a new way to give radiation to men with intermediate-risk prostate cancer. After standard radiation to the prostate and nearby glands, a precise, high-dose boost was added to the tumor. The goal was to improve cancer control while keeping side effects on the bla…

This study tested a drug called niraparib in 11 men with advanced prostate cancer that was no longer responding to hormone therapy but had recently been treated with platinum chemotherapy. The goal was to see if niraparib could keep the cancer from growing for at least 6 months. …

This study tested whether adding the drug axitinib to standard hormone therapy before surgery helps men with prostate cancer that has spread to lymph nodes. About 73 men received either hormone therapy alone or hormone therapy plus axitinib before having their prostate removed. T…

This study tested a new surgical clip called VasoClip, designed to hold blood vessels closed more securely during robotic surgery for prostate, kidney, or bladder cancer. Forty patients were randomly assigned to receive either the new clip or a standard clip. The goal was to see …

This Phase 2 study tested a radiation therapy plan that gives a slightly higher dose each day over fewer sessions (16 days instead of the usual 8-9 weeks) for men with early-stage prostate cancer. The goal was to see if this shorter schedule is safe and effective, while also trac…

This completed Phase 1/2 trial tested a combination of stereotactic body radiation therapy (5 high-dose sessions) and 4 months of hormone therapy in 45 men with intermediate-risk prostate cancer. The goal was to see how well this approach controls cancer and what side effects occ…

This study tested whether adding a precise, high-dose radiation treatment (SBRT) to the hormone therapy apalutamide helps control prostate cancer that has stopped responding to standard hormone therapy and spread to a few spots. Twenty-six men with this type of cancer took part. …

This pilot study tested whether a diet and exercise program could prevent or reduce metabolic side effects like insulin resistance and weight gain in 20 men with prostate cancer receiving hormone therapy and radiation. Participants followed dietary instructions and did aerobic an…

This study tested a new way to treat low-risk prostate cancer using MRI-guided laser ablation. Seven men with early-stage prostate cancer received the treatment to see if it was safe and could successfully destroy tumors. The goal was to target only the cancer while avoiding side…

This study tested a new type of radiation therapy called DaRT seeds for men with prostate cancer. The goal was to see if it is safe and possible to place these tiny radioactive seeds directly into the tumor before surgery. Only one person took part, and the focus was on whether t…

This study tested whether adding the drug enzalutamide to standard radiation therapy can better control prostate cancer that has come back after surgery. Eighty-six men with rising PSA levels after prostate removal took part. The goal was to see if the combination could delay can…

This early-phase study tested a highly targeted type of radiation (SBRT) in 17 men whose prostate cancer returned after prior radiation. The goal was to find the highest safe dose and see how well the body tolerated it. Participants received five focused treatments over two weeks…

This phase 2 trial tested a combination of testosterone and olaparib in 36 men with castration-resistant prostate cancer. The idea is that testosterone can cause DNA damage in cancer cells that have adapted to low testosterone, while olaparib blocks the cells' ability to repair t…

This early study tested whether adding a radioactive drug (177Lu-PSMA) to standard brachytherapy is safe and feasible for men whose prostate cancer returned after initial radiation. Only 3 men took part. The goal was to see if the combination could control cancer both in the pros…

This study tested a new way to deliver radiation for prostate cancer. The goal was to give a higher dose to the tumor while protecting the urethra and other healthy tissue. 115 men with early-stage prostate cancer took part. The researchers looked at side effects and how well the…

Researchers are testing whether a combination of PET scans with a radioactive tracer called [18F]PSMA-1007, sodium MRI, and multiparametric MRI can accurately predict where prostate cancer is and how aggressive it is. The study enrolls men who are scheduled to have their prostate…

This study is testing a new radioactive tracer called 68Ga-P16-093 for PET scans to see how well it finds prostate cancer tumors compared to standard MRI scans. About 50 people with newly diagnosed, untreated prostate cancer will receive both scans before their prostate removal s…

This study tested a new blood test called EPISPOT to find prostate cancer cells in the blood of 361 men with localized prostate cancer before they received any treatment. The goal was to see if this test could predict remission better than an existing test called CellSearch. The …

This completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …

This Phase 3 study tested a radioactive tracer called Copper Cu 64 PSMA I&T, given as an injection, to improve PET/CT scans in 235 men with prostate cancer that may have returned after initial treatment (surgery or radiation). The goal was to see how accurately the scan could det…

This study tested a fluorescent dye called IS-002 that makes prostate cancer cells glow under special lights during robotic surgery. Fifty-nine men with prostate cancer received the dye before surgery, and surgeons used a special camera to see the glowing areas. The goal was to s…

This study tests a new way to give radiotherapy for men with intermediate-risk prostate cancer. The goal is to lower the dose to healthy parts of the prostate while boosting the dose to the tumor, using a special MRI-guided machine (MR-linac). Twenty men will take part to see if …

This phase II trial tests whether flibanserin, a drug approved for low sexual desire in women, can increase sexual interest in men with prostate cancer who are receiving androgen deprivation therapy (hormone therapy). About 44 men will be randomly assigned to take flibanserin or …

This study tested whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, could lower PSA levels in 34 men with early-stage prostate cancer. The goal was to see if the drug blocks testosterone's effect on cancer growth. If it works, it might o…

This study tested whether a supplement made from muscadine grapes could reduce fatigue and improve quality of life in 106 men with prostate cancer who were already receiving hormone therapy (androgen deprivation therapy). Participants took either the grape extract or a placebo fo…

This early-phase trial tested a dye called Illuminare-1 that makes nerves glow during prostate cancer surgery. The goal was to find a safe dose that helps surgeons avoid damaging nerves, which can cause side effects like incontinence. The study involved 41 men undergoing standard…

This study looks at whether providing cancer care at home is a good option for Black men with advanced prostate cancer. Researchers want to see if this approach can reduce healthcare disparities and improve quality of life. Participants will fill out questionnaires about their pr…

This study looks at genes in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will analyze tissue, blood, and urine samples from 92 patients receiving a drug called abiraterone. The goal is to find genetic changes that …

This trial investigates how a single injection of degarelix, a drug that lowers testosterone, affects prostate cancer cells when given just days before prostate removal surgery. Researchers aim to measure changes in cell growth (Ki-67 levels) by comparing biopsy and surgical tiss…

This early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…

This study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal …

This early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identi…

This study looked at how DNA from tumors changes in the blood before, during, and after surgery for breast, prostate, or colon cancer. Thirty adults having curative surgery provided blood samples to measure these DNA levels. The goal was to understand the natural pattern of DNA c…

This study looked at whether giving prostate cancer survivors more detailed survivorship care plans helps them get better follow-up care for heart health. The study involved 550 men who had radiation and hormone therapy, which can increase risks for diabetes and heart problems. R…